| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Immunology and Muscular Pathology Unit, National Neurological Institute "C. Besta," Milan, Italy;
Department of Pathology, University of Brescia Medical School, Brescia, Italy;
Gruppo di ImmunoEndocrinologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche, Napoli, Italy;
Applied Quantum Medical Engineering, Graduate School of Engineering, Tohoku University, Sendai, Japan; and
¶ Department of Pathology,
|| Department of Neurology and Neurological Sciences, and
# Interdepartmental Program in Immunology, Stanford University, Stanford, CA 94305
Histamine can modulate the cytokine network and influence Th1 and Th2 balance and Ab-isotype switching. Thus, pharmacological blockade or genetic deletion of specific histamine receptors has been shown to reduce the severity of experimental autoimmune encephalomyelitis (EAE), a prototypic Th1-mediated disease with similarities to human multiple sclerosis. To study the comprehensive contribution of endogenous histamine to the expression of EAE, we attempted to induce EAE in histidine decarboxylase-deficient mice, which are genetically unable to make histamine. In this study, we show that EAE is significantly more severe in HDC–/–, histamine-deficient mice, with diffuse inflammatory infiltrates, including a prevalent granulocytic component, in the brain and cerebellum. Unlike splenocytes from wild-type mice, splenocytes from HDC–/– mice do not produce histamine in response to the myelin Ag, whereas production of IFN-
, TNF, and leptin are increased in HDC–/– splenocytes in comparison to those from wild-type mice. Endogenous histamine thus appears to regulate importantly the autoimmune response against myelin and the expression of EAE, in this model, and to limit immune damage to the CNS. Understanding which receptor(s) for histamine is/are involved in regulating autoimmunity against the CNS might help in the development of new strategies of treatment for EAE and multiple sclerosis.
This article has been cited by other articles:
|
|
 |
|
  S. Piconese, G. Gri, C. Tripodo, S. Musio, A. Gorzanelli, B. Frossi, R. Pedotti, C. E. Pucillo, and M. P. Colombo Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation Blood, September 24, 2009; 114(13): 2639 - 2648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Haas, O. A. Sergeeva, and O. Selbach Histamine in the Nervous System Physiol Rev, July 1, 2008; 88(3): 1183 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cortes-Canteli, R. Luna-Medina, M. Sanz-SanCristobal, A. Alvarez-Barrientos, A. Santos, and A. Perez-Castillo CCAAT/enhancer binding protein {beta} deficiency provides cerebral protection following excitotoxic injury J. Cell Sci., April 15, 2008; 121(8): 1224 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Teuscher, M. Subramanian, R. Noubade, J. F. Gao, H. Offner, J. F. Zachary, and E. P. Blankenhorn Central histamine H3 receptor signaling negatively regulates susceptibility to autoimmune inflammatory disease of the CNS PNAS, June 12, 2007; 104(24): 10146 - 10151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Furuta, K. Nakayama, Y. Sugimoto, A. Ichikawa, and S. Tanaka Activation of Histidine Decarboxylase through Post-translational Cleavage by Caspase-9 in a Mouse Mastocytoma P-815 J. Biol. Chem., May 4, 2007; 282(18): 13438 - 13446. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
